17 assets in T-Cell And NK-Cell Neoplasm

Therapeutic assets addressing T-Cell And NK-Cell Neoplasm, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cyclophosphamide T-Cell And NK-Cell Neoplasm	New York Medical College	P3	BBB (72)
Fludarabine T-Cell And NK-Cell Neoplasm	Masonic Cancer Center, University of Minnesota	P3	BB (68)
Dexasone T-Cell And NK-Cell Neoplasm	National Cancer Institute (NCI)	P1	CCC (53)
Itnk Cell Therapy T-Cell And NK-Cell Neoplasm	Second Affiliated Hospital of Guangzhou Medical University	P1/2	CCC (48)
Autologous Cd7 Car T-Cell T-Cell And NK-Cell Neoplasm	Beijing GoBroad Hospital	P1/2	CC (47)
New Donor-Derived Cd7 Car T-Cell T-Cell And NK-Cell Neoplasm	Beijing GoBroad Hospital	P1/2	CC (47)
Prior-Hsct Donor-Derived Cd7 Car T-Cell T-Cell And NK-Cell Neoplasm	Beijing GoBroad Hospital	P1/2	CC (47)
Mabel Ctls T-Cell And NK-Cell Neoplasm	Baylor College of Medicine	P1	CC (43)
Adriamycin T-Cell And NK-Cell Neoplasm	New York Medical College	Early P1	C (39)
Brentuximab Vedotin T-Cell And NK-Cell Neoplasm	New York Medical College	Early P1	C (39)
Calaspargase Pegol T-Cell And NK-Cell Neoplasm	New York Medical College	Early P1	C (39)
Etoposide T-Cell And NK-Cell Neoplasm	New York Medical College	Early P1	C (39)
Isocyclophosphamide T-Cell And NK-Cell Neoplasm	New York Medical College	Early P1	C (39)
Methotrexate T-Cell And NK-Cell Neoplasm	New York Medical College	Early P1	C (39)
Pralatraxate T-Cell And NK-Cell Neoplasm	New York Medical College	Early P1	C (39)
Prednisone T-Cell And NK-Cell Neoplasm	New York Medical College	Early P1	C (39)
ela026 T-Cell And NK-Cell Neoplasm	Electra Therapeutics Inc.	P1	NR ()